Work

Macrophage membrane-biomimetic bimetallic manganese-platinum nanozymes ameliorate intrapulmonary oxidative stress and inflammation in experimental COPD

Year: 2026

Type: article

Abstract: Chronic obstructive pulmonary disease (COPD) is characterized by persistent oxidative stress and inflammation, for which current antioxidant therapies lack efficiency and targeting. Here, we developed macrophage membrane-biomimetic bimetallic manganese-platinum nanozymes (MM-BiMP NZs) for targeted pulmonary delivery. The synthesized MM-BiMP NZs retained potent scavenging activity against multiple reactive oxygen species (ROS), including hydroxyl radicals, singlet oxygen, and superoxide anions. Using an acute lipopolysaccharide-induced lung injury model, we determined 2.5 mg/kg as a safe and effective dose for intratracheal administration. In a cigarette smoke-induced COPD mouse model, treatment with MM-BiMP NZs significantly attenuated pulmonary oxidative stress, reduced inflammatory cytokine levels, improved lung function, and ameliorated emphysema and airway remodeling. The vitro experiments demonstrated that MM-BiMP NZs were efficiently internalized, mitigated cigarette smoke extract-induced oxidative damage, and suppressed pro-inflammatory cytokine release both in the bronchial epithelial cells and alveolar macrophages. Mechanistically, transcriptomic and biochemical analyses revealed that the therapeutic effects of MM-BiMP NZs were mediated through the inhibition of the ROS-PI3K-AKT signaling pathway. This study presents a novel biomimetic nanoplatform that effectively targets the pulmonary microenvironment, combats oxidative stress, and alleviates experimental COPD, offering a promising strategy for this debilitating disease.

Source: Journal of Nanobiotechnology

DOI: 10.1186/s12951-026-04352-y